Clinical Trials Logo

Tumors Metastatic to Brain clinical trials

View clinical trials related to Tumors Metastatic to Brain.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02312622 Completed - Clinical trials for Tumors Metastatic to Brain

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Start date: August 2015
Phase: Phase 2
Study type: Interventional

This phase 2 trial evaluates how well pegylated irinotecan (NKTR-102) works in treating patients with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), or breast cancer (mBC) that has spread to the brain and does not respond to treatment. Pegylated irinotecan may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT02107755 Completed - Liver Metastases Clinical Trials

Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic Melanoma

Start date: September 5, 2014
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effectiveness of the combination of stereotactic radiation therapy and ipilimumab in patients with metastatic melanoma that has spread to four or fewer sites in the body (oligometastatic). Stereotactic radiation therapy is a type of external beam radiation therapy that uses special equipment to position the patient and precisely give a either a single large dose of radiation therapy to a tumor or several large doses of radiation therapy to a tumor using precision and accuracy that is guided by onboard daily imaging prior to radiation therapy. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some monoclonal antibodies find tumor cells and help kill them or carry tumor-killing substances to them. Giving stereotactic radiosurgery together with ipilimumab may kill more tumor cells by causing addition melanoma antigens to be presented to the immune system.

NCT ID: NCT01703507 Completed - Stage IV Melanoma Clinical Trials

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

Start date: November 9, 2012
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ipilimumab when given together with whole brain radiation therapy or stereotactic radiosurgery in treating patients with melanoma with brain metastases. Monoclonal antibodies, such as ipilimumab, can block tumor growth in different ways. Some block the ability of the tumor to grow and spread. Others find Tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy, such uses high-energy x-rays and other types of radiation to kill tumor cells. Giving radiation therapy in different ways may kill more tumor cells. Giving ipilimumab together with whole-brain radiation therapy or stereotactic radiosurgery may kill more tumor cells.

NCT ID: NCT01276210 Completed - Clinical trials for Tumors Metastatic to Brain

Sorafenib Tosylate and Stereotactic Radiosurgery in Treating Patients With Brain Metastases

Start date: February 2011
Phase: Phase 1
Study type: Interventional

RATIONALE: Sorafenib tosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor. Stereotactic radiosurgery (SRS) may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Giving sorafenib tosylate together with SRS may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and the best dose of sorafenib tosylate when given together with SRS in treating patients with brain metastases

NCT ID: NCT01234740 Completed - Adult Glioblastoma Clinical Trials

Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases

Start date: December 2010
Phase: Phase 1
Study type: Interventional

RATIONALE: Bafetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial studies bafetinib in treating patients with recurrent high-grade glioma or brain metastases.

NCT ID: NCT00992602 Completed - Clinical trials for Stage IV Breast Cancer

Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer

Start date: April 2011
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well giving liposomal cytarabine and high-dose methotrexate works in treating patients with breast cancer that has spread to the central nervous system. Drugs used in chemotherapy, such as liposomal cytarabine and methotrexate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving liposomal cytarabine with high-dose methotrexate may kill more tumor cells.

NCT ID: NCT00098605 Completed - Clinical trials for HER2-positive Breast Cancer

Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth. This phase II trial is studying how well lapatinib works in treating brain metastases in patients with stage IV breast cancer and brain metastases.

NCT ID: NCT00072163 Completed - Stage IV Melanoma Clinical Trials

Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma

Start date: October 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well giving temozolomide together with thalidomide works in treating patients with brain metastases secondary to melanoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining temozolomide with thalidomide may kill more tumor cells

NCT ID: NCT00033254 Completed - Clinical trials for Tumors Metastatic to Brain

Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases

Start date: March 2002
Phase: Phase 3
Study type: Interventional

Randomized phase III trial to compare the effectiveness of radiation therapy with or without thalidomide in treating patients who have brain metastases. Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as thalidomide may stop the growth of brain metastases by stopping blood flow to the tumor. It is not yet known whether radiation therapy is more effective with or without thalidomide in treating brain metastases.